(OPTR- Video Included!) - PWRM, JRCC, JMBA, JHX - Stock Update by Stock-Pr.com

Stock-PR Reporting

FREE Daily Stock Alerts From Stock-PR.com

________________________________________

Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) is a biopharmaceutical company Headquarted in San Diego, Ca. Optimer is focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer Pharmaceuticals has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted Optimer Pharmaceuticals’ request for six-month Priority Review of fidaxomicin, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. Optimer Pharmaceuticals also filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea.

Optimer Pharmaceuticals, Inc. recently reported the presentation of information from insurance claims and survey databases highlighting the unmet need for targeted therapies to treat subpopulations at high risk of recurrence of Clostridium difficile infection (CDI). The research also presented the substantial mortality and frequent complications associated with CDI.

Investigator Erik R. Dubberke, M.D., M.S.P.H., of the Washington University School of Medicine, St. Louis, Missouri, presented data at the 21st Annual Scientific Meeting of The Society for Healthcare Epidemiology of America (SHEA) in Dallas, Texas. Data for this research were obtained from the 2008 Nationwide Inpatient Sample, 2009 Medicare Provider Analysis and Review file, Florida fiscal year 2006-2007 Medicaid claims and 2007-2008 Medicare 5% Standard Analytical Files.

Dr. Dubberke recently presented the demographic and clinical characteristics of hospital inpatient CDI cases showing that the average CDI patient was 68 years old, more than half were female, and in total, 83% of CDI cases surveyed were from at least one of the following subpopulations: patients with renal impairment (36%), patients aged greater than age 80 (34%), patients aged 65-79 (33%), cancer patients (16%), inflammatory bowel disease patients (5%), organ transplant patients (2%), human immunodeficiency virus (HIV) patients (1%), or bone marrow transplant patients (0.4%). Each of these subpopulations are considered to be at high risk of recurrence or mortality from CDI.

In addition, Dr. Dubberke also presented data showing that Medicare was the largest payer in the CDI cases surveyed (68%), followed by private insurance (19%), and Medicaid (8%). Almost a third (31%) of the Medicare CDI hospital stays (initial or re-hospitalizations) included services in the intensive care unit (ICU) with an average length of stay in the ICU of 8.2 days. Almost two-thirds (62%) of the Medicare CDI hospital stays (initial or re-hospitalizations) included services in semi-private rooms with an average length of stay in semi-private rooms of 9.5 days. We believe the study highlights the substantial economic burden of both acute and recurrent CDI. The dreaded outcomes – recurrence and death – are seen more commonly in the elderly and those with serious underlying diseases.

About Clostridium difficile Infection (CDI)

Clostridium difficile infection (CDI), commonly referred to as “C. difficile” or “c-diff”, has become a significant medical problem in hospitals, long-term care facilities, and in the community and is estimated to afflict more than 700,000 people each year in the U.S. It is a serious illness resulting from infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death. Patients typically develop CDI from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, thus allowing C. difficile bacteria to flourish and produce toxins.

About Fidaxomicin

Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). In two Phase 3 trials for the treatment of CDI, fidaxomicin was equally effective in clinical cure when compared to vancomycin, the only FDA approved product for CDI. In two Phase 3 trials for the treatment of CDI, fidaxomicin was equally effective in clinical cure when compared to vancomycin, the only FDA approved product for CDI. Fidaxomicin also demonstrated statistically significant reduction in recurrences and an increase in global cure rate, defined as cure without recurrence.

Importantly, fidaxomicin reduced the risk of recurrence by 47% compared to vancomycin.

Additional information can be found at www.optimerpharma.com

******

Power3 Medical Products, Inc. (OTCBB:PWRM.OB), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, recently announced that company management believes it is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, to name a few.

As you’ve read this, after cancer of the skin, breast cancer is easily the most typical cancer found in women in the US. However, breast cancer statistics have dropped lately, despite the fact that medical experts are not sure as to why. Nevertheless, with regard to numerous women, breast cancer is actually the health issues they dread a great deal of.

Breast cancer is a melanoma in which cells in the breast separate and develop without regulation. Around Eighty-five percent of breast cancer occurances start out within the mammary ducts, though approximately 15% arise within the lobules. Tumors inside the chest have a tendency to develop little by little. By the point a mass might be large enough so that you can feel it, it could have been developing for as long as ten years. However, a few tumors may be aggressive, and increase considerably faster.

About Power3 Medical Products, Inc. PWRM is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases.

For information about PWRM visit: http://www.power3medical.com

******

James River Coal Company (Nasdaq:JRCC) announced that it priced an offering of $275 million aggregate principal amount of 7.875% senior notes due 2019 (the “Senior Notes”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States to non-U.S. persons in compliance with Regulation S under the Securities Act.

James River Coal Company, through its subsidiaries, engages in mining, processing, and selling bituminous, steam- and industrial-grade coal in eastern Kentucky and southern Indiana. It conducts mining operations in Bell County, Bledsoe, Blue Diamond, Leeco, and Triad mining complexes.

******

Jamba, Inc. (NASDAQ:JMBA) reported financial results for the fiscal year and fourth quarter ended December 28, 2010. The Company showed solid progress on key strategic priorities, including the expansion of food, successful commercialization of consumer products and global franchise expansion. The Company said that positive Company-owned comparable store sales during the fourth quarter–the first since 2007–signals a planned return to positive Company-owned comparable store sales for 2011.

Jamba, Inc. is a holding company and through its wholly-owned subsidiary, Jamba Juice Company, owns and franchises JAMBA JUICE® stores. Founded in 1990, Jamba Juice is a leading restaurant retailer of better-for-you food and beverage offerings, including great tasting fruit smoothies, juices, and teas, hot oatmeal made with organic steel cut oats, wraps, salads, sandwiches, and California Flatbreads™, and a variety of baked goods and snacks.

******

James Hardie Building Products Inc. (NYSE:JHX) pledges its commitment and support to small and independent replacement contractors and remodelers with the introduction of its new Associate Contractor™ Program.

James Hardie is the global leader in fiber cement technology, providing both panel and siding solutions to architects, builders and homeowners for over 100 years. It was the first to introduce fiber cement products to the U.S. in the early 1990s as a durable, low-maintenance alternative to wood and vinyl.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).

Sign Up For Free Stock Alerts At http://stock-pr.com/signup

________________________________________

Be Sure To Visit stock-pr.ning.com

**********************************************************************

The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.